Insulin biosimilar - Julphar

Drug Profile

Insulin biosimilar - Julphar

Alternative Names: Julphar Insulin R; Jusline R; Recombinant human insulin - Julphar; Regular insulin human biosimilar - Julphar; Soluble human insulin biosimilar - Julphar

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Julphar Gulf Pharmaceutical Industries
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top